Exact Sciences Corp

Exact Sciences Corp Stock Forecast & Price Prediction

Live Exact Sciences Corp Stock (EXAS) Price
$63.29

8

Ratings

  • Buy 8
  • Hold 0
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$63.29

P/E Ratio

-17.88

Volume Traded Today

$3.1M

Dividend

Dividends not available for EXAS

52 Week High/low

100.77/58.37

Exact Sciences Corp Market Cap

$11.35B

🛑 Alert: These ten stocks could have higher potential than $EXAS 🛑

Before you buy EXAS you’ll want to see this list of ten stocks that have huge potential. Want to see if EXAS made the cut? Enter your email below

EXAS Summary

From what 8 stock analysts predict, the share price for Exact Sciences Corp (EXAS) might increase by 46.36% in the next year. This is based on a 12-month average estimation for EXAS. Price targets go from $82.00 to $100.00. The majority of stock analysts believe EXAS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

EXAS Analyst Ratings

Exact Sciences Corp has a total of 8 Wall St Analyst ratings. There are 8 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Exact Sciences Corp will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

EXAS stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

catherine ramsey schulte
Robert W. Baird

Buy

$82.0

maintained

Jan 29, 2024
alexander nowak
Craig-Hallum

Buy

None

rated

Jan 8, 2024
bruce jackson
Benchmark Co.

Buy

$91.0

rated

Jan 8, 2024
daniel arias
Stifel Nicolaus

Buy

$100.0

maintained

Jan 8, 2024
puneet souda
Leerink Partners

Buy

None

maintained

Jan 7, 2024
derik de bruin
Bank of America Securities

Buy

$88.0

maintained

Jan 7, 2024
mark massaro
BTIG

Buy

$90.0

maintained

Jan 1, 2024
kyle mikson cfa
Canaccord Genuity

Buy

$100.0

maintained

Dec 19, 2023
doug schenkel
Wolfe Research

Buy

$95.0

initiatedcoverage

Dec 12, 2023
brandon couillard
Jefferies

Buy

$95.0

maintained

Nov 27, 2023
david westenberg
Piper Sandler

Buy

$80.0

maintained

Nov 6, 2023
matthew sykes
Goldman Sachs

Buy

$90.0

maintained

Nov 3, 2023
patrick b donnelly
Citi

Buy

$100.0

maintained

Nov 2, 2023
daniel brennan
TD Cowen

Buy

$100.0

maintained

Nov 1, 2023
eve burstein
Bernstein

Buy

$83.0

initiatedcoverage

Sep 28, 2023
dan leonard
Credit Suisse

Hold

$90.0

maintained

Aug 2, 2023
vijay kumar
Evercore ISI

Buy

$96.0

maintained

Aug 2, 2023
andrew brackmann
William Blair

Buy

None

maintained

Jun 21, 2023
andrew cooper
Raymond James

Hold

None

downgraded

Jan 18, 2023
kevin degeeter
Oppenheimer

Buy

$155.0

reiterated

Feb 23, 2022

EXAS Company Information

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXAS
Exact Sciences Corp (EXAS)

When did it IPO

2001

Staff Count

6,300

Country

United States

Sector/Industry

Healthcare/Diagnostics & Research

CEO

Mr. Kevin T. Conroy

Market Cap

$11.35B

Exact Sciences Corp (EXAS) Financial Data

In 2023, EXAS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that EXAS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

N/A

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year

Revenue From 2023

N/A

0.00 %
From Previous Year
  • Revenue TTM $2.41B
  • Operating Margin TTM -10.4%
  • Gross profit TTM $1.51B
  • Return on assets TTM -3.4%
  • Return on equity TTM -9.1%
  • Profit Margin -11.7%
  • Book Value Per Share 17.26%
  • Market capitalisation $11.35B
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • Revenue for 2023 N/A
  • EPS this year (TTM) $-1.58
... ...

Similar Stocks to Exact Sciences Corp - EXAS

🛑 Alert: These ten stocks could have higher potential than $EXAS 🛑

Before you buy EXAS you’ll want to see this list of ten stocks that have huge potential. Want to see if EXAS made the cut? Enter your email below

...

EXAS Frequently asked questions

The highest forecasted price for EXAS is $100.00 from daniel brennan at TD Cowen.

The lowest forecasted price for EXAS is $82.00 from catherine ramsey schulte from Robert W. Baird

The EXAS analyst ratings consensus are 8 buy ratings, 0 hold ratings, and 0 sell ratings.